The score is driven primarily by weak financial performance—zero/very low revenue, recurring losses, and mostly negative operating/free cash flow—partially cushioned by moderate leverage and stable equity. Technicals are neutral with mixed moving-average positioning and weak momentum, while valuation remains unattractive due to loss-making earnings and no stated dividend support.
Positive Factors
Balance sheet leverage and equity stability
Moderate debt-to-equity (~0.9x) and relatively stable equity give the company structural breathing room versus highly leveraged peers. This balance-sheet posture can preserve access to credit and absorb shocks while management works to restore operating performance over the medium term.
Occasional positive EBITDA
Intermittent positive EBITDA suggests underlying operations can generate operating cash before depreciation/amortization and one-offs. If revenue recovery initiatives succeed, these positive underlying margins could convert to sustainable operating profitability without requiring immediate structural changes.
Industry positioning (Specialty Chemicals)
Operating in specialty chemicals typically implies technical know‑how, higher barriers to entry and niche customer relationships. These structural industry characteristics can support pricing power and durable customer contracts, offering a realistic pathway to rebuild revenues if operational execution improves.
Negative Factors
Revenue collapse to zero
A drop to zero reported annual revenue is a severe structural impairment: it eliminates natural cash inflows, undermines customer relationships and market presence, and makes medium‑term recovery dependent on reestablishing sales channels or securing external funding to sustain operations.
Persistent negative cash generation
Consistently negative operating and free cash flows indicate ongoing cash burn and limited internal financing capability. Over months this constrains investment, working capital, and creditor flexibility, increasing reliance on external capital and raising solvency risk if losses persist.
Recurring net losses and negative returns
Chronic net losses and persistently negative ROE signal the balance sheet is not creating shareholder value. This undermines the company’s ability to retain talent, attract new capital on reasonable terms, and sustain long‑term operations without strategic restructuring or capital injections.
Seya Industries Ltd. (SEYAIND) vs. iShares MSCI India ETF (INDA)
Market Cap
₹451.17M
Dividend YieldN/A
Average Volume (3M)2.13K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees28
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.35
Shares Outstanding26,570,540
10 Day Avg. Volume0
30 Day Avg. Volume2,135
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Seya Industries Ltd. Business Overview & Revenue Model
Company DescriptionSeya Industries Limited manufactures and sells specialty chemicals in India and internationally. The company's products include pigment intermediates, chloro benzenes, nitro chloro benzenes, and acids. It offers its products for use in computer printing inks, pigments and paints, pharmaceuticals, personal and health care products, agrochemicals, insecticides/pesticides, organic chemical intermediates, rubber chemicals, textile dyes, thermic fluids, etc. The company was formerly known as Sriman Organic Chemical Industries Limited and changed its name to Seya Industries Limited in June 2011. Seya Industries Limited was incorporated in 1990 and is based in Mumbai, India.
How the Company Makes Money
Seya Industries Ltd. Financial Statement Overview
Summary
Financials indicate high operating stress: revenue has contracted sharply and fell to zero in FY2025, profitability is consistently negative with recurring net losses, and operating/free cash flow are mostly negative. The main offset is a comparatively more stable balance sheet with moderate leverage (~0.9x debt-to-equity) and intact equity, but persistently negative returns and cash burn elevate risk.
Income Statement
14
Very Negative
Operating performance is weak and volatile. Revenue has contracted sharply over the period and fell to zero in FY2025 (annual), following already low sales levels in FY2024. Profitability remains negative with recurring net losses (including a very large loss in FY2021) and negative operating profit in most years. A key positive is that EBITDA is sometimes positive despite losses, but the overall earnings quality and consistency are poor.
Balance Sheet
42
Neutral
Leverage appears moderate for a specialty chemicals profile, with debt-to-equity hovering around ~0.9x across years, and equity remaining sizable and relatively stable. However, returns are persistently negative (return on equity is below zero each year provided), indicating the balance sheet is not generating adequate shareholder value and could face pressure if losses and weak revenues persist.
Cash Flow
18
Very Negative
Cash generation is inconsistent and generally weak. Operating cash flow is negative in most years (including FY2023–FY2025), with only FY2022 showing a meaningful positive inflow. Free cash flow is also mostly negative (including a large outflow in FY2020), suggesting ongoing cash burn and limited internally funded flexibility.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026